Upgrade to SI Premium - Free Trial

Pfizer (PFE) PT Raised to $47 at BMO Capital; Sees Tafamidis as a $3.5B+ Drug

September 6, 2018 8:27 AM
BMO Capital analyst Alex Arfaei raised the price target on Pfizer (NYSE: PFE) to $47.00 (from $44.00) while maintaining an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles